PainChek Teams with Eldermark to Unlock US Long-Term Care Market
PainChek Limited has secured a pivotal reseller and integration deal with Eldermark Software, positioning its AI-driven pain assessment app for a major US market rollout pending FDA approval.
- Reseller and integration agreement with Eldermark Software LLC
- Access to Eldermark’s 116,000+ long-term care client users in the US
- Sales contingent on FDA De Novo clearance for PainChek Adult App
- Seamless integration into Eldermark’s care management system
- Focus on improving pain management accuracy and caregiver efficiency
Strategic Partnership to Enter US Market
PainChek Limited (ASX: PCK), known for its pioneering smartphone-based pain assessment technology, has announced a significant partnership with Eldermark Software LLC, a leading US care management system provider. This reseller and integration agreement aims to introduce PainChek’s AI-powered pain assessment solution to the expansive US long-term care sector, leveraging Eldermark’s established network of over 116,000 client users.
Technology Integration and Market Potential
The collaboration will see PainChek’s platform integrated directly into Eldermark’s care management system, enabling real-time access to advanced pain assessment tools that combine artificial intelligence with facial recognition technology. This integration is designed to streamline workflows for caregivers, enhance diagnostic accuracy, and ultimately improve the quality of life for residents in senior living facilities.
While the financial impact of the agreement remains unquantified at this stage, the partnership represents a strategic foothold for PainChek in the US market, which is increasingly prioritizing digital health solutions to address the complexities of pain management in aging populations.
Regulatory Milestone Pending
Importantly, the commencement of sales under this agreement is contingent upon PainChek receiving FDA De Novo clearance for its Adult App. This regulatory milestone is eagerly anticipated, as it would mark a critical step in validating PainChek’s technology for widespread clinical use in the US. The company’s CEO, Philip Daffas, highlighted the partnership as a key milestone in expanding US presence ahead of this clearance.
Broader Implications for Pain Management
PainChek’s technology addresses a significant challenge in healthcare: accurately assessing pain in individuals who cannot reliably self-report, such as those with dementia or other cognitive impairments. By automating and standardizing pain assessments, the app reduces subjectivity and caregiver burden, while supporting compliance and funding documentation through its analytics suite.
With regulatory approvals already secured in multiple countries and a growing client base exceeding 1,800 aged care facilities globally, this US partnership could accelerate PainChek’s growth trajectory and set a new standard for digital pain management solutions.
Bottom Line?
As PainChek awaits FDA clearance, its alliance with Eldermark could redefine pain care in US senior living—watch closely for regulatory updates.
Questions in the middle?
- When exactly will PainChek receive FDA De Novo clearance for its Adult App?
- How quickly can Eldermark’s network adopt and scale PainChek’s technology post-clearance?
- What measurable impact will this partnership have on PainChek’s revenue and US market share?
